Skip to main content

Table 2 Parasitological and clinical outcomes among patients treated for P. falciparum malaria with artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ), by year and site (2005-2009)

From: Surveillance of the efficacy of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum among children under five in Togo, 2005-2009

 

Non-PCR-corrected

PCR-corrected

Drug

Site

Year

n

excl/loss

ACPR

LCF

LPF

TF

(%)

(Exact 95% CI)

excl/loss

ACPR

LCF

LPF

TF

(%)

(Exact 95% CI)

Kaplan-Meier

AL

Dapaong

2005

75

1

71

3

0

3

(4.1)

(0.8-11.4)

4

71

0

0

0

(0.0)

(0.0-5.1)

0.0 (0.0-0.0)

AL

Dapaong

2009

82

0

73

2

7

9

(11.0)

(5.1-19.8)

9

73

0

0

0

(0.0)

(0.0-4.9)

0.0 (0.0-0.0)

AL

Kouvé

2005

78

3

65

4

6

10

(13.3)

(6.6-23.2)

10

65

0

3

3

(4.4)

(0.9-12.4)

4.1 (1.3-12.2)

AL

Kouvé

2009

84

0

68

2

14

16

(19.1)

(11.3-29.1)

16

68

0

0

0

(0.0)

(0.0-5.3)

0.0 (0.0-0.0)

AL

Lomé

2007

86

7

72

4

3

7

(8.9)

(3.6-17.4)

13

72

1

0

1

(1.4)

(0.0-7.4)

1.3 (0.2-8.8)

AL

Niamtougou

2005

76

0

67

1

8

9

(11.8)

(5.6-21.3)

7

67

1

1

2

(2.9)

(0.4-10.1)

2.7 (0.7-10.5)

AL

Niamtougou

2007

82

1

56

10

15

25

(30.9)

(21.1-42.1)

26

56

0

0

0

(0.0)

(0.0-6.4)

0.0 (0.0-0.0)

AL

Sokodé

2007

82

6

66

2

8

10

(13.2)

(6.5-22.9)

15

66

0

1

1

(1.5)

(0.0-8.0)

1.4 (0.2-9.7)

AL

Overall

 

645

18

538

28

61

89

(14.2)

(11.6-17.2)

100

538

2

5

7

(1.3)

(0.3-4.1)

1.2 (0.5-26.2)

ASAQ

Dapaong

2005

75

0

74

0

1

1

(1.3)

(0.0-7.2)

1

74

0

0

0

(0.0)

(0.0-4.9)

0.0 (0.0-0.0)

ASAQ

Dapaong

2009

81

0

74

1

6

7

(8.6)

(3.5-17.0)

6

74

1

0

1

(1.3)

(0.0-7.2)

1.3 (0.2-8.8)

ASAQ

Kouvé

2005

78

3

72

0

3

3

(4.0)

(0.8-11.4)

6

72

0

0

0

(0.0)

(0.0-5.1)

0.0 (0.0-0.0)

ASAQ

Kouvé

2009

85

1

78

2

4

6

(7.1)

(2.7-14.9)

7

78

0

0

0

(0.0)

(0.0-4.6)

0.0 (0.0-0.0)

ASAQ

Lomé

2007

85

3

79

1

2

3

(3.7)

(0.8-10.3)

6

79

0

0

0

(0.0)

(0.0-4.6)

0.0 (0.0-0.0)

ASAQ

Niamtougou

2005

77

2

63

1

11

12

(16.0)

(8.6-26.3)

10

63

0

4

4

(6.0)

(1.7-14.6)

5.6 (2.1-14.2)

ASAQ

Niamtougou

2007

83

6

66

3

8

11

(14.3)

(7.4-24.1)

16

66

0

1

1

(1.5)

(0.0-8.0)

1.3 (0.2-9.1)

ASAQ

Sokodé

2007

87

4

74

1

8

9

(10.8)

(5.1-19.6)

13

74

0

0

0

(0.0)

(0.0-4.9)

0.0 (0.0-0.0)

ASAQ

Overall

 

651

19

580

9

43

52

(8.2)

(6.2-10.6)

65

580

1

5

6

(1.0)

(0.3-3.5)

1.0 (0.3-2.2)

  1. ACPR: adequate clinical and parasitological response; LCF: late clinical failure; LPF: late parasitological failure; TF: treatment failures (TF = LCF + LPF).